---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022488"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:14:10.843212+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ono exercises option to Fate's HER2 CAR T-cell candidate; Fate to receive $12.5M

## Summary
- Ono exercised option to FT825/ONO-8250, triggering $12.5M option exercise fee to Fate.
- Fate and Ono to jointly develop and commercialize the candidate in the U.S. and Europe; Ono has exclusive rights elsewhere.
- Preclinical data showed broad, potent anti-tumor activity against HER2-low tumor cells.
- Fate eligible for additional clinical, regulatory, and commercial milestones plus tiered royalties on sales outside US/EU.
- Collaboration expanded to include a second solid tumor antigen program for preclinical development.

## SEC filing metadata
- accession: 0000950170-22-022488
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/0000950170-22-022488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/fate-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022488
- JSON: https://secwatch.observer/filing/0000950170-22-022488.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022488.txt

## Key facts
- Material Agreements
  FATE THERAPEUTICS INC entered into Letter Agreement with Ono Pharmaceutical Co., Ltd. valued at $12.5 million (effective 2022-11-07).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Ono Pharmaceutical Co., Ltd.
  - Value: $12.5 million
  - Effective: 2022-11-07
  source text: On November 7, 2022, Fate Therapeutics, Inc. (“Fate”) and Ono Pharmaceutical Co., Ltd. (“Ono”) entered into a letter agreement (“Letter Agreement”) in connection with the Collaboration and Option Agreement between Fate and Ono dated September 14, 2018, as amended by a letter agreement dated December 4, 2020 and an amendment dated June 28, 2022 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/0000950170-22-022488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.